RxDoctor Payments Data

Nicole Smith, APRN

Psychiatric/Mental Health · Batesville, ARNPI 1225736325

Payments from drug & device makers

$981in general payments, 2019–2025

Across 49 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$193
  • AbbVie$178
  • Johnson & Johnson$157
  • Otsuka America Pharmaceutical, Inc.$116
  • Axsome Therapeutics, Inc.$112
  • Lundbeck LLC$104
  • plus $122 from 4 others

What the payments were for

  • Food & beverage$981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$981 in reported general payments places this provider in the 50th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$15,131
Medicare patients
35
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$45,194
CaplytaLumateperone Tosylate11$18,110
RexultiBrexpiprazole12$17,373
BelsomraSuvorexant19$8,368
TrintellixVortioxetine Hydrobromide15$7,026
Desvenlafaxine Succinate ErDesvenlafaxine Succinate94$3,381
Doxepin Hcl94$1,750
Quetiapine Fumarate66$1,452
Buspirone Hcl82$1,385
Aripiprazole37$1,383
Clozapine12$1,350
Vilazodone Hcl11$946
Bupropion XlBupropion Hcl67$876
Trazodone Hcl104$826
Mirtazapine32$808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$178$45,19431 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$193$18,11011 claims
Otsuka America Pharmaceutical, Inc.Rexulti$116$17,37312 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$23$7,02615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Batesville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →